419 related articles for article (PubMed ID: 33864629)
21. Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Patel D
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):28-42. PubMed ID: 32910489
[TBL] [Abstract][Full Text] [Related]
22. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
[TBL] [Abstract][Full Text] [Related]
23. Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States.
Johnston SS; Nguyen H; Cappell K; Nelson JK; Chu BC; Kalsekar I
J Med Econ; 2015; 18(9):666-77. PubMed ID: 25867133
[TBL] [Abstract][Full Text] [Related]
24. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics.
García-Pérez LE; Boye KS; Rosilio M; Jung H; Heitmann E; Norrbacka K; Federici MO; Gentilella R; Guerci B; Giorgino F; Aigner U; Sapin H
Diabetes Ther; 2021 Jul; 12(7):1929-1946. PubMed ID: 34097244
[TBL] [Abstract][Full Text] [Related]
25. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes.
Giorgino F; Guerci B; Füchtenbusch M; Lebrec J; Boye K; Orsini Federici M; Heitmann E; Dib A; Yu M; Sapin H; García-Pérez LE
Diabetes Obes Metab; 2023 Dec; 25(12):3465-3477. PubMed ID: 37700627
[TBL] [Abstract][Full Text] [Related]
26. Glycemic Control and Weight Outcomes for Exenatide Once Weekly Versus Liraglutide in Patients with Type 2 Diabetes: A 1-Year Retrospective Cohort Analysis.
McAdam-Marx C; Nguyen H; Schauerhamer MB; Singhal M; Unni S; Ye X; Cobden D
Clin Ther; 2016 Dec; 38(12):2642-2651. PubMed ID: 27889301
[TBL] [Abstract][Full Text] [Related]
27. A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus.
Kayaniyil S; Lozano-Ortega G; Bennett HA; Johnsson K; Shaunik A; Grandy S; Kartman B
Diabetes Ther; 2016 Mar; 7(1):27-43. PubMed ID: 26886440
[TBL] [Abstract][Full Text] [Related]
28. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study.
Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K
Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.
Trujillo J
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):43-60. PubMed ID: 32910487
[TBL] [Abstract][Full Text] [Related]
30. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella R; Pechtner V; Corcos A; Consoli A
Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
[TBL] [Abstract][Full Text] [Related]
31. Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Courtney H; Nayar R; Rajeswaran C; Jandhyala R
Diabetes Metab Syndr Obes; 2017; 10():79-87. PubMed ID: 28331351
[TBL] [Abstract][Full Text] [Related]
32. Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6-month follow-up from US real-world data.
Mody R; Yu M; Nepal B; Konig M; Grabner M
Diabetes Obes Metab; 2021 Jan; 23(1):106-115. PubMed ID: 32945083
[TBL] [Abstract][Full Text] [Related]
33. Changes in Heart Rate Associated with Exenatide Once Weekly: Pooled Analysis of Clinical Data in Patients with Type 2 Diabetes.
Marso SP; Hardy E; Han J; Wang H; Chilton RJ
Diabetes Ther; 2018 Apr; 9(2):551-564. PubMed ID: 29397532
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies.
Morieri ML; Rigato M; Frison V; Simioni N; D'Ambrosio M; Tadiotto F; Paccagnella A; Lapolla A; Avogaro A; Fadini GP
Metabolism; 2020 May; 106():154190. PubMed ID: 32109448
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
Divino V; DeKoven M; Hallinan S; Varol N; Wirta SB; Lee WC; Reaney M
Diabetes Ther; 2014 Dec; 5(2):499-520. PubMed ID: 25366334
[TBL] [Abstract][Full Text] [Related]
36. Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study.
Anthony MS; Aroda VR; Parlett LE; Djebarri L; Berreghis S; Calingaert B; Beachler DC; Crowe CL; Johannes CB; Juhaeri J; Lanes S; Pan C; Rothman KJ; Saltus CW; Walsh KE
Diabetes Care; 2024 Apr; 47(4):712-719. PubMed ID: 38363873
[TBL] [Abstract][Full Text] [Related]
37. Exenatide Once Weekly for Management of Type 2 Diabetes: A Review.
Inaishi J; Saisho Y
Clin Pharmacol; 2022; 14():19-26. PubMed ID: 35422660
[TBL] [Abstract][Full Text] [Related]
38. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
[TBL] [Abstract][Full Text] [Related]
39. The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
Basson M; Ntais D; Ayyub R; Wright D; Lowin J; Chartier F; Roze S; Norrbacka K
Diabetes Ther; 2018 Feb; 9(1):13-25. PubMed ID: 29134607
[TBL] [Abstract][Full Text] [Related]
40. Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy.
Bzowyckyj A
J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):7-16. PubMed ID: 32910488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
